SCHEMBL760581

SCHEMBL760581

CN(C)c1cccc(C(=O)Nc2n[nH]c3ccc(N)cc23)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ULK1 O75385 1/20 0.53
MEN1 O00255 1/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
KMT2A Q03164 1/20 0.48
CDK7 P50613 6/20 0.47
GSK3B P49841 1/20 0.46
JAK2 O60674 4/20 0.46
JAK1 P23458 4/20 0.46
FLT3 P36888 2/20 0.46
CDC7 O00311 1/20 0.46
DAPK3 O43293 1/20 0.46
ROCK2 O75116 1/20 0.46
MAP4K4 O95819 1/20 0.46
PAK4 O96013 1/20 0.46
PRKACA P17612 1/20 0.46
CDK2 P24941 1/20 0.46
CSNK1A1 P48729 1/20 0.46
CLK2 P49760 1/20 0.46
CDK9 P50750 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14404444 0.84 MEN1 (0.46) ULK1MEN1NPC1RAB9AKMT2A
SCHEMBL761113 0.83 JAK2 (0.62) ULK1CDK7GSK3BJAK2JAK1
SCHEMBL759280 0.83 CDK2 (0.55) MEN1NPC1RAB9AKMT2ACDK7
SCHEMBL758654 0.82 CDK7 (0.58) ULK1MEN1NPC1RAB9AKMT2A
SCHEMBL10269234 0.80 MAPKAPK2 (0.49) ULK1MEN1NPC1RAB9AKMT2A
SCHEMBL627302 0.75 GSK3B (0.60) ULK1GSK3BJAK2DAPK3CDK2
SCHEMBL6816845 0.74 MAPT (0.62) MEN1NPC1RAB9AKMT2AKDM4E
SCHEMBL6782639 0.73 BTK (0.64) NPC1RAB9AKDM4EALDH1A1MAPT
SCHEMBL14514465 0.72 MAP2K4 (0.55) ULK1JAK2JAK1NTRK1
SCHEMBL1335092 0.72 NTRK1 (0.61) ULK1CDK7JAK2JAK1FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053345-A1 Indazole Compounds ABBOTT LABORATORIES (US) 2012-03-01 US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070282101-A1 Indazole compounds CYP3A43, CYP3A7, UGT1A1 ULK1 1214/4885MEN1 878/4885NPC1 58/4885
US-20120053345-A1 Indazole Compounds CYP3A43, CYP3A7, UGT1A1 ULK1 1214/4885MEN1 878/4885NPC1 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.